- Home
- HYPR vs BEAT Comparison
HYPR vs BEAT Comparison
Compare HYPR & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYPR
- BEAT
- Stock Information
- Founded
- HYPR 2014
- BEAT 2015
- Country
- HYPR United States
- BEAT United States
- Employees
- HYPR N/A
- BEAT N/A
- Industry
- HYPR Medical Specialities
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- HYPR Health Care
- BEAT Technology
- Exchange
- HYPR Nasdaq
- BEAT Nasdaq
- Market Cap
- HYPR 55.9M
- BEAT 51.1M
- IPO Year
- HYPR N/A
- BEAT 2021
- Fundamental
- Price
- HYPR $0.80
- BEAT $1.30
- Analyst Decision
- HYPR Strong Buy
- BEAT Buy
- Analyst Count
- HYPR 3
- BEAT 1
- Target Price
- HYPR $1.06
- BEAT $8.00
- AVG Volume (30 Days)
- HYPR 631.1K
- BEAT 169.5K
- Earning Date
- HYPR 08-07-2025
- BEAT 08-13-2025
- Dividend Yield
- HYPR N/A
- BEAT N/A
- EPS Growth
- HYPR N/A
- BEAT N/A
- EPS
- HYPR N/A
- BEAT N/A
- Revenue
- HYPR $11,732,000.00
- BEAT N/A
- Revenue This Year
- HYPR $12.31
- BEAT N/A
- Revenue Next Year
- HYPR $29.29
- BEAT N/A
- P/E Ratio
- HYPR N/A
- BEAT N/A
- Revenue Growth
- HYPR 0.34
- BEAT N/A
- 52 Week Low
- HYPR $0.53
- BEAT $1.17
- 52 Week High
- HYPR $1.90
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- HYPR 58.62
- BEAT 36.38
- Support Level
- HYPR $0.70
- BEAT $1.17
- Resistance Level
- HYPR $0.77
- BEAT $1.62
- Average True Range (ATR)
- HYPR 0.05
- BEAT 0.11
- MACD
- HYPR 0.00
- BEAT -0.02
- Stochastic Oscillator
- HYPR 93.33
- BEAT 21.96
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.